The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 first-in-human dose finding/randomized phase 2 study of IMM60 and pembrolizumab (PEM) in advanced melanoma and non–small cell lung cancer (NSCLC; IMP-MEL).
 
Nicholas Coupe
No Relationships to Disclose
 
Ian B. Walters
Employment - Intensity Therapeutics; Portage Biotech; SalvaRx
Leadership - Enzo Biochem; Intensity Therapeutics; Portage Biotech; SalvaRx
Stock and Other Ownership Interests - Enzo Biochem; Intensity Therapeutics; Portage Biotech; SalvaRx
 
Robert A. Kramer
Employment - Portage Biotech; SalvaRx
Leadership - Portage Biotech; SalvaRx
Stock and Other Ownership Interests - Portage Biotech; SalvaRx
 
Uzi Gileadi
Stock and Other Ownership Interests - SalvaRx
Consulting or Advisory Role - SalvaRx
 
Mark R. Middleton
Consulting or Advisory Role - Alkermes; Bayer; BiolineRx; Boehringer Ingelheim; Bristol-Myers Squibb; Immunocore; Kineta; Merck; Silicon Therapeutics; Vaccitech
Research Funding - Amgen (Inst); AstraZeneca (Inst); BiolineRx (Inst); Bristol-Myers Squibb (Inst); GRAIL (Inst); Immunocore (Inst); Medivir (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Replimune (Inst); Roche (Inst); Salvarx (Inst); Vaccitech (Inst)
(OPTIONAL) Uncompensated Relationships - GenesisCare